Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

e-Therapeutics director buys shares with fees

The group said he subscribed for 36,917 new shares at 7.45p each worth around £2,750.

Non-exec director at drug discovery firm e-Therapeutics plc (LON:ETX) Professor Trevor Jones has bought shares in the company instead of taking part of his fees.

The group said he subscribed for 36,917 new shares at 7.45p each worth around £2,750.

In October, Professor Jones entered into a binding contractual arrangement where he agreed, with effect from October 1 last year to invest 50% of his annual non-executive director fees net of tax in new e-Therapeutics' stock.

He will now be interested in around 107,497 shares, or around 0.04% of the capital.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK